Literature DB >> 7755364

Intracerebral involvement in scleroderma en coup de sabre: report of a case with neuropathologic findings.

M H Chung1, J Sum, M J Morrell, D S Horoupian.   

Abstract

Linear scleroderma en coup de sabre (LScs) is a rare disorder not infrequently associated with neurologic symptoms, notably epilepsy. However, histopathologic documentation of intracerebral lesions in LScs is very limited and the etiology of the central nervous system symptoms has therefore never been convincingly established. We describe a 27-year-old woman with LScs and a longstanding history of epilepsy. Radiographic studies demonstrated a focal, intraparenchymal lesion in the left frontal lobe directly subjacent to the area of scleroderma on the forehead and scalp. The resected cerebral lesion revealed localized band-like sclerosis of the leptomeninges and associated vessels, as well as intraparenchymal calcifications and anomalous, ectatic vessels. These findings suggest that LScs may represent a neurocutaneous syndrome of vascular dysplasia similar to the Sturge-Weber syndrome, rather than a localized form of collagen vascular disease, as suggested by some.

Entities:  

Mesh:

Year:  1995        PMID: 7755364     DOI: 10.1002/ana.410370519

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

Review 1.  Systemic manifestations in localized scleroderma.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

Review 2.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

3.  Hemifacial atrophy: a neurocutaneous disorder with coup de sabre deformity, telangiectatic naevus, aneurysmatic malformation of the internal carotid artery and crossed hemiatrophy.

Authors:  H Strenge; P Cordes; M Sticherling; J Brossmann
Journal:  J Neurol       Date:  1996-09       Impact factor: 4.849

4.  Difficulties in differentiation of Parry-Romberg syndrome, unilateral facial sclerodermia, and Rasmussen syndrome.

Authors:  Justyna Paprocka; Ewa Jamroz; Dariusz Adamek; Elzbieta Marszal; Marek Mandera
Journal:  Childs Nerv Syst       Date:  2005-10-25       Impact factor: 1.475

Review 5.  The central nervous system manifestations of localized craniofacial scleroderma: a study of 10 cases and literature review.

Authors:  Ezekiel Maloney; Sarah J Menashe; Ramesh S Iyer; Sarah Ringold; Amit K Chakraborty; Gisele E Ishak
Journal:  Pediatr Radiol       Date:  2018-07-03

6.  Longstanding epileptic encephalopathy and linear localized scleroderma: two distinct pathologic processes in an adolescent.

Authors:  Donato Rigante; Domenica Battaglia; Ilaria Contaldo; Ilaria La Torraca; Laura Avallone; Stefania Gaspari; Giulia Bersani; Achille Stabile
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

7.  A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings.

Authors:  Yvonne E Chiu; Sheetal Vora; Eun-Kyung M Kwon; Mohit Maheshwari
Journal:  Pediatr Dermatol       Date:  2012 Nov-Dec       Impact factor: 1.588

8.  Brain MRI screening showing evidences of early central nervous system involvement in patients with systemic sclerosis.

Authors:  Reem Hamdy A Mohammed; Yousriah Y Sabry; Amr A Nasef
Journal:  Rheumatol Int       Date:  2010-01-13       Impact factor: 2.631

9.  Neurologic involvement in scleroderma en coup de sabre.

Authors:  Tiago Nardi Amaral; João Francisco Marques Neto; Aline Tamires Lapa; Fernando Augusto Peres; Caio Rodrigues Guirau; Simone Appenzeller
Journal:  Autoimmune Dis       Date:  2012-01-27

Review 10.  Progressive hemifacial atrophy: a review.

Authors:  Stanislav N Tolkachjov; Nirav G Patel; Megha M Tollefson
Journal:  Orphanet J Rare Dis       Date:  2015-04-01       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.